Finance

Beta
Lists
PHVS:NASDAQ
Pharvaris NV
$34.01
+2.13%
(+0.71) 1D
Jun 26, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PHVS...
Open
$33.53
High
$34.06
Low
$32.93
Mkt. cap
2.37B
Avg. vol.
333.94K
Volume
519.30K
52-wk high
$35.32
52-wk low
$16.72
EPS
-$3.12
Beta
-2.34
Shares outstanding
69.86M
No. of employees
134
Open
$33.53
High
$34.06
Low
$32.93
Mkt. cap
2.37B
Avg. vol.
333.94K
Volume
519.30K
52-wk high
$35.32
52-wk low
$16.72
EPS
-$3.12
Beta
-2.34
Shares outstanding
69.86M
No. of employees
134
News stories
From sources across the web
About Pharvaris NV
CEO-
Employees134
Founded2015
Headquarters-
SectorPharmaceutical industry
Websitepharvaris.com
Analyst ratings
Based on 10 analysts giving stock ratings to PHVS in the past 3 months
Strong buy
Buy
9
Hold
1
Sell
0
12-month forecast
Based on 10 Wall Street analysts offering 12 month price targets for PHVS in the last 3 months.
Highest
Current $34.01
$74.00 (+117.58%)
Average
$49.60 (+45.84%)
Lowest
$33.00 (-2.97%)
Analyst
Recommendation
Action
Price target
Projected
Date
Maxwell Skor
Morgan Stanley
Buy
Reiterated
$46.00
+35.3%
06/25/2026
Patrick Trucchio
H.C. Wainwright
Buy
Reiterated
$60.00
+76.4%
06/16/2026
Debanjana Chatterjee
JonesTrading
Buy
Maintained
$52.00
+52.9%
06/11/2026
Tazeen Ahmad
Bank of America Securities
Hold
Maintained
$33.00
-3%
05/14/2026
Laura Chico
Wedbush
Buy
Maintained
$42.00
+23.5%
05/13/2026
Jeff Jones
Oppenheimer
Buy
Reiterated
$50.00
+47%
05/13/2026
Steven Seedhouse
Cantor Fitzgerald
Buy
Reiterated
$46.00
+35.3%
05/12/2026
Nevin Varghese
RBC Capital
Buy
Maintained
$51.00
+50%
05/12/2026
Jonathan Wolleben
Citizens JMP
Buy
Maintained
$74.00
+117.6%
05/13/2026
Andy Chen
Wolfe Research
Buy
Initiated
$42.00
+23.5%
04/08/2026
Unknown Analyst
RBC Capital
Buy
Initiated
$52.00
+52.9%
03/09/2026
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in EUR
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
29.61M
29.81M
34.14M
30.16M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10.77M
9.85M
13.46M
14.11M
Operating expense
40.37M
39.66M
47.60M
44.27M
Total operating expenses
40.37M
39.66M
47.60M
44.27M
Operating income
-40.37M
-39.66M
-47.60M
-44.27M
Other non operating income
-38.13K
-
-
-86.40K
EBT including unusual items
-45.28M
-37.32M
-45.08M
-38.93M
EBT excluding unusual items
-45.28M
-37.32M
-45.08M
-38.93M
Income tax expense
202.78K
-181.47K
1.66M
273.11K
Effective tax rate
-0.45%
0.49%
-3.69%
-0.70%
Other operating expenses
-
-
-
-
Net income
-45.48M
-37.14M
-46.74M
-39.20M
Net profit margin
-
-
-
-
Earnings per share
-0.83
-0.60
-0.71
-0.60
Interest and investment income
1.00M
2.15M
2.19M
1.67M
Interest expense
-
-50.03K
-58.74K
-
Net interest expenses
1.00M
2.10M
2.13M
1.67M
Depreciation and amortization charges
-
-
-
-
EBITDA
-40.33M
-39.62M
-47.55M
-44.22M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
Give me an overview of PHVS
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer